Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Cinzia, Pellegrini"'
Autor:
Gianmarco Bagnato, Vittorio Stefoni, Alessandro Broccoli, Lisa Argnani, Cinzia Pellegrini, Beatrice Casadei, Francesca Bonifazi, Pier Luigi Zinzani
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 16, Iss 1 (2024)
We report the case of 2 patients with relapsed/refractory peripheral T-cell lymphoma treated with valemetostat tosilate, a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zeste homolog 1 and 2, and subsequently bridged to
Externí odkaz:
https://doaj.org/article/f3bcfe6454db4c48926e6d674464f884
Autor:
Lisa Argnani, Alessandro Broccoli, Cinzia Pellegrini, Alberto Fabbri, Benedetta Puccini, Riccardo Bruna, Maria Chiara Tisi, Francesco Masia, Leonardo Flenghi, Maria Elena Nizzoli, Maurizio Musso, Marilena Salerno, Potito Rosario Scalzulli, Daniela Dessi’, Isacco Ferrarini, Elsa Pennese, Elisa Lucchini, Francesca Gaia Rossi, Carla Minoia, Filippo Gherlinzoni, Pellegrino Musto, Caterina Patti, Vittorio Stefoni, Pier Luigi Zinzani
Publikováno v:
HemaSphere, Vol 6, Iss 12, p e798 (2022)
After FDA and EMA approval of the regimen containing polatuzumab vedotin plus rituximab and bendamustine (PolaBR), eligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients in Italy were granted early access through a Named Patient
Externí odkaz:
https://doaj.org/article/1cc1af983bd1486091a4adbd8c7747a9
Autor:
Beatrice Casadei, Lisa Argnani, Alice Morigi, Ginevra Lolli, Alessandro Broccoli, Cinzia Pellegrini, Laura Nanni, Vittorio Stefoni, Paolo E. Coppola, Matteo Carella, Michele Cavo, Pier Luigi Zinzani
Publikováno v:
Cancer Medicine, Vol 9, Iss 21, Pp 7830-7836 (2020)
Abstract Programmed death‐1 (PD1) blockade is an efficient and safe therapeutic option in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, a substantial proportion of patients’ progresses or loses the response to
Externí odkaz:
https://doaj.org/article/59e93f11c511493180f4ed9f296c34cc
Autor:
Umberto Pensato, Giulia Amore, Lorenzo Muccioli, Susanna Sammali, Francesca Rondelli, Rita Rinaldi, Roberto D’Angelo, Marianna Nicodemo, Susanna Mondini, Luisa Sambati, Gian Maria Asioli, Simone Rossi, Rossella Santoro, Lucia Cretella, Susy Ferrari, Luca Spinardi, Luca Faccioli, Stefano Fanti, Andrea Paccagnella, Elisabetta Pierucci, Beatrice Casadei, Cinzia Pellegrini, Pier Luigi Zinzani, Massimiliano Bonafè, Pietro Cortelli, Francesca Bonifazi, Maria Guarino
Publikováno v:
Journal of Neurology. 270:2659-2673
Autor:
Vittorio Stefoni, Miriam Marangon, Alessandro Re, Arben Lleshi, Maurizio Bonfichi, Antonello Pinto, Nicola Bianchetti, Cinzia Pellegrini, Lisa Argnani, Pier Luigi Zinzani
Publikováno v:
Haematologica, Vol 105, Iss 10 (2020)
Externí odkaz:
https://doaj.org/article/62ca266e777f4117ad9ca9001d34a070
Autor:
Beatrice Casadei, Alessandro Broccoli, Vittorio Stefoni, Cinzia Pellegrini, Miriam Marangon, Alice Morigi, Laura Nanni, Ginevra Lolli, Matteo Carella, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
Publikováno v:
Haematologica, Vol 104, Iss 11 (2019)
Externí odkaz:
https://doaj.org/article/7ba1ac885aea4513b53503f182ef2591
Autor:
Alessandro Broccoli, Beatrice Casadei, Vittorio Stefoni, Cinzia Pellegrini, Federica Quirini, Lorenzo Tonialini, Alice Morigi, Miriam Marangon, Lisa Argnani, Pier Luigi Zinzani
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background The purpose of this study is to investigate the most suitable first-line approach and the best combination treatment for primary mediastinal large B-cell lymphoma (PMLBCL) as they have been matter of debate for at least two decade
Externí odkaz:
https://doaj.org/article/57025dcd6c6441119dc1a81a2b6a4fa4
Autor:
Cinzia Pellegrini, Anna Dodero, Annalisa Chiappella, Federico Monaco, Debora Degl’Innocenti, Flavia Salvi, Umberto Vitolo, Lisa Argnani, Paolo Corradini, Pier Luigi Zinzani, On behalf of the Italian Lymphoma Foundation (Fondazione Italiana Linfomi Onlus, FIL)
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-7 (2016)
Abstract Background There is no consensus regarding optimal treatment for peripheral T-cell lymphomas (PTCL), especially in relapsed or refractory cases, which have very poor prognosis and a dismal outcome, with 5-year overall survival of 30 %. Metho
Externí odkaz:
https://doaj.org/article/7f63a7964ca947f0bb87ef0dba8b2cf2
Autor:
Alessandro Broccoli, Cinzia Pellegrini, Alice Di Rocco, Benedetta Puccini, Caterina Patti, Guido Gini, Donato Mannina, Monica Tani, Chiara Rusconi, Alessandra Romano, Anna Vanazzi, Barbara Botto, Carmelo Carlo-Stella, Stefan Hohaus, Pellegrino Musto, Patrizio Mazza, Stefano Molica, Paolo Corradini, Angelo Fama, Francesco Gaudio, Michele Merli, Angela Gravetti, Giuseppe Gritti, Annalisa Arcari, Patrizia Tosi, Anna Marina Liberati, Antonello Pinto, Vincenzo Pavone, Filippo Gherlinzoni, Virginia Naso, Stefano Volpetti, Livio Trentin, Maria Cecilia Goldaniga, Maurizio Bonfichi, Amalia De Renzo, Corrado Schiavotto, Michele Spina, Sergio Storti, Angelo Michele Carella, Vittorio Stefoni, Lisa Argnani, Pier Luigi Zinzani
Publikováno v:
Haematologica, Vol 102, Iss 11 (2017)
Between November 2012 and July 2014, in accordance with national law 648/96, brentuximab vedotin was available in Italy for patients with relapsed systemic anaplastic large cell lymphoma outside a clinical trial context. A large Italian observational
Externí odkaz:
https://doaj.org/article/a663cbb1e87b4e5a949b59a8ab0a0e7f
Autor:
Alessandro Broccoli, Lisa Argnani, Laura Nanni, Gianmarco Bagnato, Matteo Carella, Beatrice Casadei, Paolo Elia Coppola, Gabriele Gugliotta, Ginevra Lolli, Marianna Gentilini, Alice Morigi, Cinzia Pellegrini, Vittorio Stefoni, Pier Luigi Zinzani
Publikováno v:
Blood. 140:6526-6527